261 related articles for article (PubMed ID: 26514880)
1. Pharmacokinetic properties of IgG and various Fc fusion proteins in mice.
Unverdorben F; Richter F; Hutt M; Seifert O; Malinge P; Fischer N; Kontermann RE
MAbs; 2016; 8(1):120-8. PubMed ID: 26514880
[TBL] [Abstract][Full Text] [Related]
2. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.
Suzuki T; Ishii-Watabe A; Tada M; Kobayashi T; Kanayasu-Toyoda T; Kawanishi T; Yamaguchi T
J Immunol; 2010 Feb; 184(4):1968-76. PubMed ID: 20083659
[TBL] [Abstract][Full Text] [Related]
3. Qualification of a homogeneous cell-based neonatal Fc receptor (FcRn) binding assay and its application to studies on Fc functionality of IgG-based therapeutics.
Mathur A; Arora T; Liu L; Crouse-Zeineddini J; Mukku V
J Immunol Methods; 2013 Apr; 390(1-2):81-91. PubMed ID: 23384837
[TBL] [Abstract][Full Text] [Related]
4. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
[TBL] [Abstract][Full Text] [Related]
5. A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life.
Souders CA; Nelson SC; Wang Y; Crowley AR; Klempner MS; Thomas W
MAbs; 2015; 7(5):912-21. PubMed ID: 26018774
[TBL] [Abstract][Full Text] [Related]
6. Targeting the neonatal fc receptor for antigen delivery using engineered fc fragments.
Mi W; Wanjie S; Lo ST; Gan Z; Pickl-Herk B; Ober RJ; Ward ES
J Immunol; 2008 Dec; 181(11):7550-61. PubMed ID: 19017944
[TBL] [Abstract][Full Text] [Related]
7. Half-life extension of a single-chain diabody by fusion to domain B of staphylococcal protein A.
Unverdorben F; Färber-Schwarz A; Richter F; Hutt M; Kontermann RE
Protein Eng Des Sel; 2012 Feb; 25(2):81-8. PubMed ID: 22238430
[TBL] [Abstract][Full Text] [Related]
8. Immunoglobulin Fc domain fusion to apolipoprotein(a) kringle V significantly prolongs plasma half-life without affecting its anti-angiogenic activity.
Yu HK; Lee HJ; Ahn JH; Lim IH; Moon JH; Yoon Y; Yi LS; Kim SJ; Kim JS
Protein Eng Des Sel; 2013 Jun; 26(6):425-32. PubMed ID: 23571426
[TBL] [Abstract][Full Text] [Related]
9. The N-terminal alanine-extended GLP-1/IgG-Fc fusion protein confers resistance to DPP-IV and reduces serum glucose level in db/db mice.
Chung HS; Oh JY; Yoo SB; Lee SM; Cho HS
Regul Pept; 2011 Oct; 170(1-3):1-3. PubMed ID: 21621561
[TBL] [Abstract][Full Text] [Related]
10. An engineered affibody molecule with pH-dependent binding to FcRn mediates extended circulatory half-life of a fusion protein.
Seijsing J; Lindborg M; Höidén-Guthenberg I; Bönisch H; Guneriusson E; Frejd FY; Abrahmsén L; Ekblad C; Löfblom J; Uhlén M; Gräslund T
Proc Natl Acad Sci U S A; 2014 Dec; 111(48):17110-5. PubMed ID: 25406323
[TBL] [Abstract][Full Text] [Related]
11. The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity.
Abdiche YN; Yeung YA; Chaparro-Riggers J; Barman I; Strop P; Chin SM; Pham A; Bolton G; McDonough D; Lindquist K; Pons J; Rajpal A
MAbs; 2015; 7(2):331-43. PubMed ID: 25658443
[TBL] [Abstract][Full Text] [Related]
12. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
[TBL] [Abstract][Full Text] [Related]
13. A novel approach to investigate the effect of methionine oxidation on pharmacokinetic properties of therapeutic antibodies.
Stracke J; Emrich T; Rueger P; Schlothauer T; Kling L; Knaupp A; Hertenberger H; Wolfert A; Spick C; Lau W; Drabner G; Reiff U; Koll H; Papadimitriou A
MAbs; 2014; 6(5):1229-42. PubMed ID: 25517308
[TBL] [Abstract][Full Text] [Related]
14. Investigating the interaction between the neonatal Fc receptor and monoclonal antibody variants by hydrogen/deuterium exchange mass spectrometry.
Jensen PF; Larraillet V; Schlothauer T; Kettenberger H; Hilger M; Rand KD
Mol Cell Proteomics; 2015 Jan; 14(1):148-61. PubMed ID: 25378534
[TBL] [Abstract][Full Text] [Related]
15. Generation of mutant leukaemia inhibitory factor (LIF)-IgG heavy chain fusion proteins as bivalent antagonists of LIF.
Jazayeri JA; De Weerd N; Raye W; Velkov T; Santos L; Taylor D; Carroll GJ
J Immunol Methods; 2007 May; 323(1):1-10. PubMed ID: 17408687
[TBL] [Abstract][Full Text] [Related]
16. Enhanced Fc-dependent cellular cytotoxicity of Fc fusion proteins derived from TNF receptor II and LFA-3 by fucose removal from Asn-linked oligosaccharides.
Shoji-Hosaka E; Kobayashi Y; Wakitani M; Uchida K; Niwa R; Nakamura K; Shitara K
J Biochem; 2006 Dec; 140(6):777-83. PubMed ID: 17038352
[TBL] [Abstract][Full Text] [Related]
17. Effect of pH, temperature, and salt on the stability of Escherichia coli- and Chinese hamster ovary cell-derived IgG1 Fc.
Li CH; Narhi LO; Wen J; Dimitrova M; Wen ZQ; Li J; Pollastrini J; Nguyen X; Tsuruda T; Jiang Y
Biochemistry; 2012 Dec; 51(50):10056-65. PubMed ID: 23078371
[TBL] [Abstract][Full Text] [Related]
18. Recombinant human lactoferrin-Fc fusion with an improved plasma half-life.
Shiga Y; Oshima Y; Kojima Y; Sugimoto A; Tamaki N; Murata D; Takeuchi T; Sato A
Eur J Pharm Sci; 2015 Jan; 67():136-143. PubMed ID: 25433245
[TBL] [Abstract][Full Text] [Related]
19. Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor: relationship to pharmacokinetics in mice and primates.
Datta-Mannan A; Witcher DR; Tang Y; Watkins J; Jiang W; Wroblewski VJ
Drug Metab Dispos; 2007 Jan; 35(1):86-94. PubMed ID: 17050651
[TBL] [Abstract][Full Text] [Related]
20. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics.
Schoch A; Kettenberger H; Mundigl O; Winter G; Engert J; Heinrich J; Emrich T
Proc Natl Acad Sci U S A; 2015 May; 112(19):5997-6002. PubMed ID: 25918417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
